245 related articles for article (PubMed ID: 15781327)
1. Future challenges facing the development of specific active-site-directed synthetic inhibitors of MMPs.
Cuniasse P; Devel L; Makaritis A; Beau F; Georgiadis D; Matziari M; Yiotakis A; Dive V
Biochimie; 2005; 87(3-4):393-402. PubMed ID: 15781327
[TBL] [Abstract][Full Text] [Related]
2. Structural basis for the highly selective inhibition of MMP-13.
Engel CK; Pirard B; Schimanski S; Kirsch R; Habermann J; Klingler O; Schlotte V; Weithmann KU; Wendt KU
Chem Biol; 2005 Feb; 12(2):181-9. PubMed ID: 15734645
[TBL] [Abstract][Full Text] [Related]
3. Hydroxamate-based peptide inhibitors of matrix metalloprotease 2.
Jani M; Tordai H; Trexler M; Bányai L; Patthy L
Biochimie; 2005; 87(3-4):385-92. PubMed ID: 15781326
[TBL] [Abstract][Full Text] [Related]
4. Design and characterization of a metalloproteinase inhibitor-tethered resin for the detection of active MMPs in biological samples.
Hesek D; Toth M; Meroueh SO; Brown S; Zhao H; Sakr W; Fridman R; Mobashery S
Chem Biol; 2006 Apr; 13(4):379-86. PubMed ID: 16632250
[TBL] [Abstract][Full Text] [Related]
5. Synthetic active site-directed inhibitors of metzincins: achievement and perspectives.
Yiotakis A; Dive V
Mol Aspects Med; 2008 Oct; 29(5):329-38. PubMed ID: 18657570
[TBL] [Abstract][Full Text] [Related]
6. Crystal structures of MMPs in complex with physiological and pharmacological inhibitors.
Maskos K
Biochimie; 2005; 87(3-4):249-63. PubMed ID: 15781312
[TBL] [Abstract][Full Text] [Related]
7. Crystal structure of human macrophage elastase (MMP-12) in complex with a hydroxamic acid inhibitor.
Nar H; Werle K; Bauer MM; Dollinger H; Jung B
J Mol Biol; 2001 Sep; 312(4):743-51. PubMed ID: 11575929
[TBL] [Abstract][Full Text] [Related]
8. In silico study of MMP inhibition.
Rouffet M; Denhez C; Bourguet E; Bohr F; Guillaume D
Org Biomol Chem; 2009 Sep; 7(18):3817-25. PubMed ID: 19707688
[TBL] [Abstract][Full Text] [Related]
9. Insight into the structural determinants for selective inhibition of matrix metalloproteinases.
Pirard B
Drug Discov Today; 2007 Aug; 12(15-16):640-6. PubMed ID: 17706545
[TBL] [Abstract][Full Text] [Related]
10. Structural basis of the matrix metalloproteinases and their physiological inhibitors, the tissue inhibitors of metalloproteinases.
Bode W; Maskos K
Biol Chem; 2003 Jun; 384(6):863-72. PubMed ID: 12887053
[TBL] [Abstract][Full Text] [Related]
11. Mechanism of inhibition of the human matrix metalloproteinase stromelysin-1 by TIMP-1.
Gomis-Rüth FX; Maskos K; Betz M; Bergner A; Huber R; Suzuki K; Yoshida N; Nagase H; Brew K; Bourenkov GP; Bartunik H; Bode W
Nature; 1997 Sep; 389(6646):77-81. PubMed ID: 9288970
[TBL] [Abstract][Full Text] [Related]
12. Substrate specificity determinants of human macrophage elastase (MMP-12) based on the 1.1 A crystal structure.
Lang R; Kocourek A; Braun M; Tschesche H; Huber R; Bode W; Maskos K
J Mol Biol; 2001 Sep; 312(4):731-42. PubMed ID: 11575928
[TBL] [Abstract][Full Text] [Related]
13. The design of inhibitors for medicinally relevant metalloproteins.
Jacobsen FE; Lewis JA; Cohen SM
ChemMedChem; 2007 Feb; 2(2):152-71. PubMed ID: 17163561
[TBL] [Abstract][Full Text] [Related]
14. Docking studies of matrix metalloproteinase inhibitors: zinc parameter optimization to improve the binding free energy prediction.
Hu X; Shelver WH
J Mol Graph Model; 2003 Nov; 22(2):115-26. PubMed ID: 12932782
[TBL] [Abstract][Full Text] [Related]
15. A new role for old ligands: discerning chelators for zinc metalloproteinases.
Jacobsen FE; Lewis JA; Cohen SM
J Am Chem Soc; 2006 Mar; 128(10):3156-7. PubMed ID: 16522091
[TBL] [Abstract][Full Text] [Related]
16. From model complexes to metalloprotein inhibition: a synergistic approach to structure-based drug discovery.
Puerta DT; Schames JR; Henchman RH; McCammon JA; Cohen SM
Angew Chem Int Ed Engl; 2003 Aug; 42(32):3772-4. PubMed ID: 12923840
[No Abstract] [Full Text] [Related]
17. Third generation of matrix metalloprotease inhibitors: Gain in selectivity by targeting the depth of the S1' cavity.
Devel L; Czarny B; Beau F; Georgiadis D; Stura E; Dive V
Biochimie; 2010 Nov; 92(11):1501-8. PubMed ID: 20696203
[TBL] [Abstract][Full Text] [Related]
18. Structure of recombinant mouse collagenase-3 (MMP-13).
Botos I; Meyer E; Swanson SM; Lemaître V; Eeckhout Y; Meyer EF
J Mol Biol; 1999 Oct; 292(4):837-44. PubMed ID: 10525409
[TBL] [Abstract][Full Text] [Related]
19. X-ray structure of human stromelysin catalytic domain complexed with nonpeptide inhibitors: implications for inhibitor selectivity.
Pavlovsky AG; Williams MG; Ye QZ; Ortwine DF; Purchase CF; White AD; Dhanaraj V; Roth BD; Johnson LL; Hupe D; Humblet C; Blundell TL
Protein Sci; 1999 Jul; 8(7):1455-62. PubMed ID: 10422833
[TBL] [Abstract][Full Text] [Related]
20. Development of a receptor-based 3D-QSAR study for the analysis of MMP2, MMP3, and MMP9 inhibitors.
Tuccinardi T; Nuti E; Ortore G; Rossello A; Avramova SI; Martinelli A
Bioorg Med Chem; 2008 Aug; 16(16):7749-58. PubMed ID: 18640045
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
